glp level 1 Glucagon-like peptide-1 GLP-1 and the Gut–Musculoskeletal Axis:

The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation

1A, 2A)

Inhibition of lipid synthase activity: AOD 9604 reduces the activities of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), and decreases de novo synthesis of fatty acids

GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and a growing pipeline of new entrants are being prescribed to tens of millions of Americans for weight loss and diabetes management, and they are fundamentally altering how, when, and how much people eat